RSRoya Sherkat

Roya Sherkat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roya Sherkat has a total of 410 co-authors. Here are the top co-authors by number of shared publications:

  • Aryana Zamanifar

    Immunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    5 shared publications
  • Behrokh Shojaie

    Immunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    3 shared publications
  • Negin Salemi

    Immunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    3 shared publications
  • Saba Sheikhbahaei

    Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    3 shared publications
  • Alireza Emami Naeini

    Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    2 shared publications
  • Amir Bahreini

    Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, USA

    2 shared publications

Latest Publications

  • Open Access

    Immunodeficiency following rituximab therapy: clinical spectrum and monitoring strategies

    by Mahnaz Rezaei, Diba Saeidi, Vahid Shaygannejad, Fereshteh Ashtari, Somayeh Najafi, Fariba Dehghan, Narges Ebrahimi, Farzin Khorvash, Mazdak Ganjalikhani-Hakemi, Roya Sherkat

  • Open Access

    Dissecting the molecular heterogeneity of common variable immunodeficiency using an integrative multi-omics approach

    by Samira Bahrami, Fariba Dehghan, Leyla Norouzi Barough, Bahram Bagherpour, Somayeh Najafi, Behrokh Shojaie, Mohammad Reza Mofid, Roya Sherkat

  • Open Access

    Exploring Monogenic, Polygenic, and Epigenetic Models of Common Variable Immunodeficiency

    by Tayebeh Ranjbarnejad, Hassan Abolhassani, Roya Sherkat, Mansoor Salehi, Fatemeh Ranjbarnejad, Nasimeh Vatandoost, Mohammadreza Sharifi

    Common variable immunodeficiency (CVID) is the most frequent symptomatic inborn error of immunity (IEI). CVID is genetically heterogeneous and occurs in sporadic or familial forms with different inheritance patterns. Monogenic mutations have been found in a low percentage of patients, and multifactorial or polygenic inheritance may be involved in unsolved patients. In the complex disease model, the epistatic effect of multiple variants in several genes and environmental factors such as infections may contribute. Epigenetic modifications, such as DNA methylation changes, are also proposed to be involved in CVID pathogenesis. In general, the pathogenic mechanism and molecular basis of CVID disease are still unknown, and identifying patterns of association across the genome in polygenic models and epigenetic modification profiles in CVID requires more studies. Here, we describe the current knowledge of the molecular genetic basis of CVID from monogenic, polygenic, and epigenetic aspects.


  • Open Access

    Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error

    by Negin Salemi, Behrokh Shojaie, Paria Bolourinejad, Roya Sherkat, Aryana Zamanifar, Farhoodeh Ghaedrahmati, Mahdieh Azizi, Hamid Aria

    Background: The relationship between inborn errors of immunity (IEIs) and COVID-19 severity and incidence rates remains unclear due to limited and diverse data. This study aimed to address this gap by identifying specific IEIs associated with an increased risk of severe COVID-19 or a predisposition to severe disease before vaccination. Materials and Methods: Data were collected from the medical records of 15 patients with various IEIs, supplemented by interviews with individuals from an IEIs registry who had experienced COVID-19 before vaccination. Results: Among the participants, only three patients (20%) experienced severe-prolonged COVID-19. Notably, this severity was predominantly observed in two male patients with Bruton’s disease (BD) and one female patient with autosomal recessive hypogammaglobinemia. Moderate and severe COVID-19 cases were equally distributed (13.33%). In the female subgroup, one patient with common variable immunodeficiency and another with combined immunodeficiency experienced moderate and severe COVID-19, respectively. Conversely, both male patients with moderate and severe COVID-19 had BD. Conclusion: Despite the limited number of severe cases, the absence of cytokine storm manifestation suggests potential protective mechanisms, possibly due to intravenous immunoglobulin therapy and inherent deficiencies within cytokine-producing cells (B and T cells). While IEIs may not be significant risk factors for COVID-19, they offer promising avenues for further research into therapeutic strategies targeting specific immune system components to mitigate severe COVID-19.

  • The sufficiency of genetic diagnosis in managing patients with inborn errors of immunity during prenatal care and childbearing

    by Negin Salemi, Shima Bakhshesh, Amir Bahreini, Rasoul Salehi, Aryana Zamanifar, Fariba Dehghan, Roya Sherkat

    Individuals with inborn errors of immunity face challenges in fertility, pregnancy, and genetic disorder transmission. Prenatal genetic counseling is crucial, especially in tribal societies with consanguineous unions. Ten families with confirmed inborn errors of immunity were studied, revealing diverse pregnancy decisions: An architect with autosomal dominant STAT-1 gain of function underwent prenatal diagnosis despite initial plans for preimplantation genetic diagnosis. In a consanguineous family, two children died from leukocyte adhesion deficiency type 1 because the father refused prenatal diagnosis. First cousins opted against terminating the second pregnancy, resulting in two children affected by Bruton disease. Another consanguineous couple, with two children afflicted by ataxia-telangiectasia, chose oocyte donation for their third child, ensuring a healthy birth. Recurrent pregnancy loss was observed in a mother subsequently diagnosed with ZAP70 deficiency. A mother with Wiskott-Aldrich syndrome child opted for in vitro fertilization, leading to a healthy birth post-prenatal diagnosis. A misdiagnosis of anaplastic anemia occurred in a family with multiple instances of Wiskott-Aldrich syndrome. A leukocyte adhesion deficiency type 1 case led to parental dissolution due to the father’s refusal to acknowledge the condition. In a non-consanguineous couple, the father’s diagnosis of TACI deficiency influenced the mother’s decision to discontinue pregnancy post-prenatal diagnosis. Genetic diagnosis alone cannot optimize prenatal care for immune dysregulation disorders. Various factors, including patient education, societal norms, ethics, and economics, impact pregnancy decisions. Clinical immunologists must integrate these elements into guidance strategies to enhance patient outcomes.


  • B-cells absence in patients diagnosed as inborn errors of immunity: a registry-based study

    by Razieh Khoshnevisan, Shakiba Hassanzadeh, Christoph Klein, Meino Rohlfs, Bodo Grimbacher, Newsha Molavi, Aryana Zamanifar, Ali Khoshnevisan, Mahbube Jafari, Bahram Bagherpour, et al.

    Hypogammaglobulinemia without B-cells is a subgroup of inborn errors of immunity (IEI) which is characterized by a significant decline in all serum immunoglobulin isotypes, coupled with a pronounced reduction or absence of B-cells. Approximately 80 to 90% of individuals exhibit genetic variations in Bruton’s agammaglobulinemia tyrosine kinase (BTK), whereas a minority of cases, around 5–10%, are autosomal recessive agammaglobulinemia (ARA). Very few cases are grouped into distinct subcategories. We evaluated phenotypically and genetically 27 patients from 13 distinct families with hypogammaglobinemia and no B-cells. Genetic analysis was performed via whole-exome and Sanger sequencing. The most prevalent genetic cause was mutations in BTK. Three novel mutations in the BTK gene include c.115 T > C (p. Tyr39His), c.685-686insTTAC (p.Asn229llefs5), and c.163delT (p.Ser55GlnfsTer2). Our three ARA patients include a novel homozygous stop-gain mutation in the immunoglobulin heavy constant Mu chain (IGHM) gene, a novel frameshift mutation of the B-cell antigen receptor complex-associated protein (CD79A) gene, a novel bi-allelic stop-gain mutation in the transcription factor 3 (TCF3) gene. Three patients with agammaglobulinemia have an autosomal dominant inheritance pattern, which includes a missense variant in PIK3CD, a novel missense variant in PIK3R1 and a homozygous silent mutation in the phosphoinositide-3-kinase regulatory subunit (RASGRP1) gene. This study broadens the genetic spectrum of hypogammaglobulinemia without B-cells and presented a few novel variants within the Iranian community, which may also have implications in other Middle Eastern populations. Notably, disease control was better in the second affected family member in families with multiple cases.


  • Open Access

    Diversity in the clinical course and outcome of COVID-19 in patients with different inborn errors of immunity (IEIs) can be associated with type of IEIs

    by Negin Salemi, Behrokh Shojaie, Paria Bolourinejad, Roya Sherkat, Aryana Zamanifar, Farhoodeh Ghaedrahmati, Mahdieh Azizi, Hamid Aria

    Purpose: Due to limited and heterogeneous reports, there is still no information on the relationship between the type of inborn errors of immunity (IEIs) and two main parameters including the incidence rate and severity of COVID-19. Therefore, this study aims to introduce IEIs that may increase the chance of SARS‑CoV‑2 infection or have the highest probability of risk for a severe type of COVID-19 before vaccination. Methods: Data was collected through medical documents obtained from 15 patients with different IEIs and interviews with those who experienced COVID-19 before vaccination and enrolled in our IEIs registry. Results: Only three patients (20%), two men with Bruton Disease (BD) and one woman with Autosomal Recessive Hypogammaglobinemia (ARH), experienced severe-prolonged COVID-19. The frequency of patients with moderate and severe COVID-19 was equal (13.33%). In the female group, one patient with Common Variable Immunodeficiency (CVID) and one patient with Combined Immunodeficiency (CID) had moderate and severe forms of COVID-19, respectively. In contrast, both men who experienced moderate and severe COVID-19 were suffering from BD. Conclusion: Although a small number of patients with BD, CID, and ARH experienced severe and severe- prolonged COVID-19, no formation of cytokine storm was observed, probably owing to IVIG therapy and congenital disorders in the formation or function of cells producing cytokines (B&T cells). Therefore, IEIs not only cannot be a crucial risk factor for COVID-19 but also may provide a great research opportunity to find potential therapies for the prevention of severe COVID-19 through the temporary suppression of some immune system components.

  • Open Access

    Is a definite genetic diagnosis all we need to manage patients with Inborn Error of Immunity prenatally and during childbearing? Running title: Prenatal and Childbearing Considerations

    by Negin Salemi, Shima Bakhshesh, Aryana Zamanifar, Amir Bahreini, Rasoul Salehi, Roya Sherkat

    Background: Patients with inborn errors of immunity (IEI) who want to have children face concerns about the impact of their condition on fertility, pregnancy, and disease inheritance. In tribal cultures with consanguineous marriages, prenatal genetic counseling is critical. Case presentation: 10 families with genetically confirmed IEI were reported: An architect with an autosomal dominant STAT-1 gain of function who had planned preimplantation genetic diagnosis (PGD) to prevent disease transmission. However, she unexpectedly became pregnant and underwent prenatal diagnosis (PND) at 12 weeks. Despite the diagnosis, her husband refused to allow her to abort the affected child. Another case involved a consanguineous family who lost their first child to leukocyte adhesion deficiency type 1 (LAD1). The second child was also affected. Despite the availability of PND during the second pregnancy, the father refused the procedure. In another instance, a first cousin couple had two children with Bruton disease. Despite being informed about the disease, the mother refused to abort her second child. Likewise, a consanguineous couple with two children affected by Ataxia Telangiectasia opted for a donated oocyte for their third child, resulting in a healthy child. Recurrent pregnancy loss (RPL) was observed in a mother who was later diagnosed with ZAP70 deficiency. In another case, a mother with a child affected by Wiskott Aldrich Syndrome (WAS) underwent in vitro fertilization (IVF) without sex selection, resulting in a healthy boy after PND was performed during pregnancy. In a family with multiple cases of WAS, another child was mistakenly diagnosed with anaplastic anemia. A case of LAD1 resulted in the parents' divorce, with the father denying the child's condition and impeding necessary bone marrow transplantation. In a non-consanguineous couple, the father was diagnosed with TACHI deficiency and Hypogammaglobulinemia. PND revealed that the mother and child had the same heterozygote gene, leading the mother to decide against continuing the pregnancy. Conclusion: Genetic diagnosis alone is not enough for optimal prenatal care in immune dysregulation disorders. Factors like patient awareness, social beliefs, ethics, and economic considerations impact pregnancy decisions. Clinical immunologists must consider these factors and provide guidance for better outcomes.

  • Open Access

    Contradictory Effect of Lymphocyte Therapy and Prednisolone Therapy on CD3+CD8+CD56+ Natural Killer T Population in Women with Recurrent Spontaneous Abortion

    by Fatemeh Rezayat, Nafiseh Esmaeil, Abbas Rezaei, Roya Sherkat

    Background: Natural killer T (NKT) cells are influential immune cells in pregnancy failures, including recurrent spontaneous abortion (RSA). Different approaches are used for these disorders due to their effects on maternal immunomodulation. Aims: In the present study, we compared the effects of two typical immunotherapies (lymphocyte immunotherapy [LIT] and low-dose prednisolone) on CD3+CD56+CD16+ and CD3+CD56+CD8+ cells as two distinct subsets of NKT cells in Women with RSA. Settings and Design: This study was a comparative cohort study conducted from 2021 to 2022. One hundred and five women with RSA were distributed into three treatment groups randomly. Materials and Methods: Fifty women in the group of low-dose prednisolone therapy, fifty women in the LIT group and five women without any treatment as the control group were included in the study. NK and NKT cell subsets were assessed using flow cytometry. Furthermore, the concentration of interferon-gamma (IFN-γ), transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10) was measured quantitatively using the enzyme-linked immunosorbent assay technique. Statistical Analysis Used: Normality and comparisons between study groups were performed by non-parametric unpaired Mann–Whitney, Kruskal–Wallis rank sum test, and one-way ANOVA. Results: The percentage of CD56dim NK cells was increased after prednisolone therapy, while this population significantly decreased in the LIT group. In contrast to the LIT group, the administration of prednisolone increased CD3+CD8+CD56+ NKT cells (P < 0.0001), which is helpful for pregnancy. The effect of the investigated treatment approaches on the population of peripheral CD3+CD56+CD16+ NKT cells of women with RSA was not adequately significant. The same situation was also observed regarding the serum level of IFN-γ. However, a significant decrease in serum levels of IL-10 and TGF-β was observed after prednisolone therapy. Conclusion: The lower capability of LIT in changing the population of NKT cells compared to prednisolone therapy may be due to its mechanism of action, which is related to the production of blocking antibodies. These treatment approaches had different effects on NKT cells, indicating that NKT cell population and function can be affected using LIT and prednisolone therapy distinctly. In addition, prednisolone therapy and LIT in women with normal serum levels of IFN-γ have no harmful effects in changing the production of this critical cytokine.